Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Flutter Entertainment plcFLUT · Entity 1330 | Director | June 02, 2026 | June 03, 2026 |
| PFIZER INCPFE · Entity 2863 | Executive Vice President | March 04, 2025 | March 06, 2025 |
| UL Solutions Inc.ULS · Entity 1747 | Director | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Flutter Entertainment plc
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,071 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 2,071 · Balance 2,071 F1: Represents a grant of restricted stock units, which will vest on the earlier of (i) June 2, 2027 and (ii) the day prior to the first regularly scheduled annual meeting of the stockholders of the Issuer following the grant date but no earlier than 50 weeks from the date of grant, in each case, subject to the director's continued service through and including such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which will vest on the earlier of (i) June 2, 2027 and (ii) the day prior to the first regularly scheduled annual meeting of the stockholders of the Issuer following the grant date but no earlier than 50 weeks from the date of grant, in each case, subject to the director's continued service through and including such vesting date.
PFIZER INC
Report date March 04, 2025 · Filed March 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $25.75 · Expires 2030-03-04 | Direct | 156,992 |
Reported balance
After 2025-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-04 · Grant · Acquired 156,992 · Balance 156,992 F1: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
UL Solutions Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,979 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 10 · Balance 4,979 F1: Each restricted stock unit ("RSU") and deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: Represents accrual of dividend equivalent rights on DRSUs held by the Reporting Person. F3: The dividend equivalent rights accrued on DRSUs held by the Reporting Person and vest proportionately with the DRSUs to which they relate. The DRSUs vested on May 1, 2025, and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the Reporting Person pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), or (ii) as otherwise provided by the Plan. F4: Includes DRSUs and all dividend equivalent rights that have accrued on such DRSUs to date. |
| Deferred Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,814 |
Reported balance
After 2026-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-10 · Grant · Acquired 5 · Balance 2,814 F1: Each restricted stock unit ("RSU") and deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: Represents accrual of dividend equivalent rights on DRSUs held by the Reporting Person. F5: The dividend equivalent rights accrued on DRSUs held by the Reporting Person and vest proportionately with the DRSUs to which they relate. The DRSUs vested on May 20, 2026, and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the Reporting Person pursuant to the Issuer's Plan, or (ii) as otherwise provided by the Plan. F4: Includes DRSUs and all dividend equivalent rights that have accrued on such DRSUs to date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,213 |
Reported balance
After 2026-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-10 · Grant · Acquired 4 · Balance 2,213 F1: Each restricted stock unit ("RSU") and deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6: Represents accrual of dividend equivalent rights on RSUs held by the Reporting Person. F7: The dividend equivalent rights accrued on RSUs held by the Reporting Person and vest proportionately with the RSUs to which they relate. The RSUs vest on the earlier of May 20, 2027, or the date of the annual meeting following the May 20, 2026, grant date. F8: Includes RSUs and all dividend equivalent rights that have accrued on such RSUs to date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") and deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: Represents accrual of dividend equivalent rights on DRSUs held by the Reporting Person.
F3: The dividend equivalent rights accrued on DRSUs held by the Reporting Person and vest proportionately with the DRSUs to which they relate. The DRSUs vested on May 1, 2025, and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the Reporting Person pursuant to the Issuer's Non-Employee Director Deferred Compensation Plan (the "Plan"), or (ii) as otherwise provided by the Plan.
F4: Includes DRSUs and all dividend equivalent rights that have accrued on such DRSUs to date.
F5: The dividend equivalent rights accrued on DRSUs held by the Reporting Person and vest proportionately with the DRSUs to which they relate. The DRSUs vested on May 20, 2026, and will be settled in shares of the Issuer's Class A Common Stock either (i) on a date selected by the Reporting Person pursuant to the Issuer's Plan, or (ii) as otherwise provided by the Plan.
F6: Represents accrual of dividend equivalent rights on RSUs held by the Reporting Person.
F7: The dividend equivalent rights accrued on RSUs held by the Reporting Person and vest proportionately with the RSUs to which they relate. The RSUs vest on the earlier of May 20, 2027, or the date of the annual meeting following the May 20, 2026, grant date.
F8: Includes RSUs and all dividend equivalent rights that have accrued on such RSUs to date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 76,043 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,043 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 46,291 | $43.70 | $2,022,916.70 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,195 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 13,007 | $42.38 | $551,236.66 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,486 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:17 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 76,043 | $30.17 | $2,294,217.31 |
DisclosureSEC source: 0001225208-23-002831 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:34 UTC | PFIZER INC PFE · Entity 2863 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006908 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,450 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 58,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,225 Underlying: Common Stock · 58,623 shares Expires not disclosed F6 · derivative.exercise_price: Each unit represents one phantom share of common stock. F7 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon) which have been deferred into the Pfizer Inc. Deferred Compensation Plan. F8 · derivative.exercise_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F8 · derivative.expiration_date: The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 63,580 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,580 shares Expires 2022-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 29,685 | $50.64 | $1,503,248.40 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,450 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 18,745 | $47.72 | $894,511.40 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,135 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 25, 2022. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 22:55 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 63,580 | $25.60 | $1,627,648.00 |
DisclosureSEC source: 0001225208-22-003724 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:29 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 35,313 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,313 Underlying: Common Stock · 35,313 shares Expires 2029-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 23:29 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 40,151 | $0.00 Strike: $45.96 | $0.00 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,151 Underlying: Common Stock · 40,151 shares Expires 2027-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:29 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 76,895 | $0.00 Strike: $27.34 | $0.00 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,895 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:29 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 38,060 | $51.28 | $1,951,716.80 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,300 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:29 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 19,110 | $46.87 | $895,685.70 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,360 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 23:29 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 76,895 | $27.34 | $2,102,309.30 |
DisclosureSEC source: 0001225208-22-003472 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 20,520 | $54.44 | $1,117,108.80 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 14 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,575 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 12,370 | $54.64 | $675,896.80 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 13 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,095 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 3,700 | $54.55 | $201,835.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 12 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,465 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 2,279 | $54.45 | $124,091.55 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 11 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,165 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 1,130 | $54.65 | $61,754.50 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 10 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,444 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 901 | $54.56 | $49,158.56 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,574 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 800 | $54.47 | $43,576.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 8 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,475 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 700 | $54.49 | $38,143.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,275 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 700 | $54.50 | $38,150.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,975 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 400 | $54.51 | $21,804.00 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,675 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 399 | $54.53 | $21,757.47 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 4 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,075 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 250 | $54.57 | $13,642.50 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,474 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 101 | $54.48 | $5,502.48 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,724 Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 21:30 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 58 | $54.43 | $3,156.94 |
DisclosureSEC source: 0001225208-21-014219 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,825 Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 71,899 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,899 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 45,587 | $34.64 | $1,579,133.68 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,883 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 14,004 | $33.49 | $468,993.96 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,470 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 71,899 | $22.35 | $1,606,942.65 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 57,649 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,649 Underlying: Common Stock · 57,649 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 66,721 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · derivative · entry 6 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,721 Underlying: Common Stock · 66,721 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 81,667 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,667 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 52,853 | $34.76 | $1,837,170.28 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,575 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 15,335 | $33.82 | $518,629.70 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,428 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:10 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 81,667 | $22.89 | $1,869,357.63 |
DisclosureSEC source: 0001225208-21-004057 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 22:55 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 43,662 | $41.94 | $1,831,184.28 |
DisclosureSEC source: 0001225208-20-013319 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,096 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2019. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 91,408 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,408 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 47,221 | $36.45 | $1,721,205.45 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,758 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 23,517 | $33.42 | $785,938.14 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,979 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:55 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 91,408 | $27.37 | $2,501,836.96 |
DisclosureSEC source: 0001225208-20-004027 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:28 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 69,335 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · derivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,335 Underlying: Common Stock · 69,335 shares Expires 2027-02-27 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 27, 2020 Filed Feb 29, 2020 00:28 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 80,925 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · derivative · entry 8 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,925 Underlying: Common Stock · 80,925 shares Expires 2025-02-27 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:28 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 72,464 | $0.00 Strike: $34.59 | $0.00 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · derivative · entry 7 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,464 shares Expires 2020-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:28 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 55,313 | $36.80 | $2,035,518.40 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · nonDerivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,088 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:28 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 10,384 | $34.72 | $360,532.48 |
DisclosureSEC source: 0001225208-20-003803 · doc4.xml · nonDerivative · entry 4 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,401 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.